Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings PLC has demonstrated a robust commercial trajectory for its lead product, KIMMTRAK, which has consistently outperformed quarterly sales expectations in 12 out of 14 quarters since its launch. The company is well-positioned for growth, with expectations of increased penetration in the US community setting and potential expansion into additional international markets, supported by a deep pipeline of assets across oncology, infectious, and autoimmune disease areas. Furthermore, the successful approval of KIMMTRAK by both the FDA and EMA in early 2022 underscores its market reliability, contributing positively to investor sentiment regarding the company's valuation.

Bears say

Immunocore Holdings PLC faces a negative outlook primarily due to disappointing data disclosures for key clinical programs, specifically revealing a low Overall Response Rate (ORR) of 11% for cutaneous melanoma and 6% for ovarian cancer, which fell short of market expectations. Additionally, the potential for significant market erosion is exacerbated by emerging competition from IDYA's darovasertib and combination therapies that could challenge KIMMTRAK's market position in the HLA-A2+ metastatic uveal melanoma segment. Finally, the company is susceptible to risks associated with R&D and regulatory delays, potential new competitors, and challenges related to financing, which could adversely affect its financial stability and growth trajectory.

Immunocore Holdings (IMCR) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 9 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.